Shares of OS Therapies Inc (NYSE:OSTX – Get Free Report) traded up 0.3% during trading on Thursday . The company traded as high as $3.12 and last traded at $2.96. 87,270 shares were traded during trading, a decline of 64% from the average session volume of 243,689 shares. The stock had previously closed at $2.95.
Analysts Set New Price Targets
Several research analysts recently commented on OSTX shares. EF Hutton Acquisition Co. I raised shares of OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd. Brookline Capital Management raised OS Therapies to a “strong-buy” rating in a report on Thursday, August 22nd.
View Our Latest Research Report on OSTX
OS Therapies Trading Up 0.3 %
About OS Therapies
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Recommended Stories
- Five stocks we like better than OS Therapies
- What Investors Need to Know to Beat the Market
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Using the MarketBeat Dividend Tax Calculator
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for OS Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OS Therapies and related companies with MarketBeat.com's FREE daily email newsletter.